<DOC>
	<DOC>NCT02922543</DOC>
	<brief_summary>To understand the safety and efficacy of Revlimid® 5 mg Capsules (hereinafter referred to as Revlimid) in patients with "relapsed or refractory multiple myeloma" (hereinafter referred to as "relapsed or refractory MM") who have received long-term treatment with it under the actual condition of use. 1. Planned registration period This period started on the date of initial marketing of Revlimid and will end at the time when the planned number of patients to be enrolled, 300, is reached (estimated to be approximately 1 year and 3 moths). 2. Planned surveillance period This period started on the date of initial marketing of Revlimid and will end 3 years after the last enrolled patient begins receiving Revlimid (estimated to be approximately 4 years and 3 months).</brief_summary>
	<brief_title>A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Relapsed or refractory MM patients in the special useresults surveillance (allcase surveillance) (hereinafter referred to as the allcase surveillance) who have received Revlimid treatment for at least 7 cycles at institutions cooperating in performing the allcase surveillance and this surveillance.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Teratogenicity</keyword>
	<keyword>Thrombocytopenia and haemorrhage</keyword>
	<keyword>Neutropenia and infection</keyword>
	<keyword>Venous thromboembolism</keyword>
	<keyword>Allergic reactions</keyword>
	<keyword>Diarrhoea or constipation</keyword>
	<keyword>Peripheral neuropathy</keyword>
	<keyword>Cardiac failure</keyword>
	<keyword>Arrhythmia</keyword>
	<keyword>Renal failure</keyword>
	<keyword>Myocardial infarction</keyword>
	<keyword>Interstitial lung disease</keyword>
	<keyword>Tumour lysis syndrome</keyword>
</DOC>